CD274 and glioma: In vivo experiments further confirmed that D&H-A-A&C had significant anti-glioma effects, and the combination of anti-PD-L1 antibodies could alleviate the immunosuppressive microenvironment of glioma, increase the intensity of anti-tumor immune response, and the induced immune memory effect could also effectively prevent tumor recurrence.